CD8A and neoplasm: In vivo studies demonstrated that conditional deletion of BMPR-IA in T cells results in a more effective anti-tumor immune response, a higher proportion of activated anti-tumor CD8+ cells, and fewer infiltrating tumor-infiltrating Tregs (151).